Morbidity and Mortality Associated with COVID-19 and Acute Chest Syndrome in Sickle Cell Disease Patients
- 3 July 2024
- journal article
- research article
- Published by Taylor & Francis in Hemoglobin
- Vol. 48 (4) , 285-291
Abstract
SUMMARYCOVID-19 infection has emerged as a comorbidity that can significantly increase morbidity and mortality in sickle cell patients with ACS (acute thoracic/chest syndrome). The aim of our study was to assess COVID-19-related morbidity and mortality in sickle cell patients with ACS. This was a retrospective, descriptive study of patient records followed over a 36-month period from January 2020 to December 2022. The study was conducted at the national blood transfusion center in Dakar. The sex ratio (M/F) was 0.82. The median age was 26 (17-39) years. The most represented age group was between 21 and 30 years. Factors associated with death were: at baseline, SS genotype, presence of comorbidities (asthma, chronic obstructive pulmonary disease, viral hepatitis B, ischemic heart disease), osteonecrosis of the femoral head, and use of NSAIDs (non-steroidal anti-inflammatory drugs) at diagnosis of COVID-19; at the diagnosis of ACS associated with COVID-19, respiratory distress, hypoxia (Sa02 < 92%), creatininemia >18.5 mg/l, CRP >192 mg/l, lymphopenia; the therapeutic modalities associated with death were: transfusion of RBCs (packed red blood cells) and curative anticoagulation. This study shows that patients with comorbidities and/or chronic complications of sickle cell disease can develop severe forms of ACS associated with COVID 19, leading to death. Other factors linked to death, notably diagnostic and therapeutic, were also identified in the course of this study.Keywords
This publication has 27 references indexed in Scilit:
- Acute Chest Syndrome in Sickle Cell DiseaseTransfusion Medicine Reviews, 2023
- Case Fatality Rate and Severity of COVID-19 among Patients with Sickle Cell Disease: A Systematic Review and Meta-AnalysisHemoglobin, 2023
- Acute chest syndrome in the setting of SARS‐COV‐2 infections—A case series at an urban medical center in the BronxPediatric Blood & Cancer, 2020
- Prognosis of patients with sickle cell disease and COVID-19: a French experienceThe Lancet Haematology, 2020
- COVID-19 and psoriasis: biologic treatment and challengesJournal of Dermatological Treatment, 2020
- Clinical Characteristics of Coronavirus Disease 2019 in ChinaNew England Journal of Medicine, 2020
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort studyThe Lancet, 2020
- Sickle cell diseaseNature Reviews Disease Primers, 2018
- Sickle cell diseaseThe Lancet, 2017
- Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)The Lancet, 2011